QualTek Molecular Laboratories
QualTek exhibited at Cambridge Healthtech Institute’s 11th Annual Biomarkers & Diagnostics World Congress 2015, May 5-7, 2015 | Loews Philadelphia Hotel | Philadelphia, PA.
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
QualTek’s study agreement with Corcept Therapeutics has resulted in a manuscript co-authored by QualTek personnel and published in Cancer Management and Research. The manuscript details QualTek’s development and validation of an IHC assay for Glucocorticoid Receptor which is currently being utilized in clinical trials of mifepristone, a GR antagonist, in patients with Triple Negative Breast Cancer.
The PD-L1 IHC assay, reported in the following Pembrolizumab publications, was developed and validated by QualTek.
QualTek announces our shared publication with Merck and Co, Inc. scientists
Detailing the development of the prototype PD-L1 assay which we have extensively tested for various clinical studies for Keytruda® (Pembrolizumab).
March 6, 2017; QualTek is proud to share our publication with Corcept Therapeutics, Inc.
Profiling Glucocorticoid Receptor expression in 20 solid tumor types using the IHC assay developed by QualTek.
October 28, 2017; QualTek acknowledged in presentation by Mersana for the development of a novel marker IHC assay
Data from IHC testing of primary ovarian cancer xenograft models illustrated response to Mersana’s XMT-1536 when the models showed expression of NaPi2b equivalent to an H-score greater than or equal to 70. This novel IHC assay will be further evaluated in a Phase I clinical trial of XMT-1536.